CV Lattes
ResearcherID
Google Scholar Citations
Universidade de São Paulo (USP). Faculdade de Medicina de Ribeirão Preto (FMRP) (Institutional affiliation from the last research proposal) Birthplace: Brazil
CTO and R&D of NEOGENYS and Research fellow of Dana-Farber Cancer Institute/Harvard Medical School. I have the earnest motivation on dissecting molecularly pediatric brain tumors and developing novel strategies to overcome therapy resistance and developing solution to improve the precision medicine concept. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Medulloblastoma is the most common malignant central nervous system tumor in children, with an estimated 30,000 children affected worldwide each year. According to the World Health Organization (WHO), this tumor is molecularly subdivided into four subgroups: WNT, SHH (wild-type TP53 or mutated TP53), and Non-WNT/SHH (Group 3 and 4). These subgroups have distinct molecular and clinical cha…
Medulloblastoma is the most common malignant brain tumor in childhood and according to World Health Organization it is subdivided in 4 molecular subgroups: WNT, SHH, Group 3 and Group 4. SHH is divided in SHH TP53 WT and Mutated. These subgroups have distinct molecular characteristics and clinical associations, and differ in the prognosis of patients impacting the risk stratification and …
Medulloblastoma is the most common malignant brain tumor in childhood and it is the main cause of morbidity and mortality in pediatric oncolology. Recent studies revelead 4 molecular subgroups of Medulloblastomas based on the transcriptional, mutational and cytogenetic profiles, these subgroups are: WNT, SHH, Group 3 and Group 4. The SHH molecular subgrupous which bears mutation in TP53 g…
Brain tumors are the second most frequent (after leukemia) and related to death caused by cancer in infants. Medulloblastoma is a brain malignant tumor most common in childhood and have a free-disease survival rate up to 80%. The standard treatment is surgery,radiotherapy (usually in infants older thant 3 years) and chemiotherapy. Recently,based on a transcription and mutational profile …
Besides surgery, the standard treatment options for newly diagnosed medulloblastoma (MB) include radiotherapy and chemotherapy, which induce severe adverse effects and compromise the quality of life in pediatric patients. Group 2 (Sonic Hedgehog [SHH]) and Group 3 (MYC) MB tumors are highly aggressive with moderate and worst prognoses, respectively. These two subgroups also have an intact…
Medulloblastoma (MB) cell dissemination is at the origin of the leptomeningeal metastatic disease, which is a common and severe complication of this malignant, pediatric brain tumor. The molecular mechanisms that mediate MB cell dissemination are largely unknown and no targeted therapy exists to specifically block dissemination. Like many human tumors, MB disease is complex and consists o…
Medulloblastoma is the most common brain cancer in childhood. The treatment available is surgery, chemiotherapy and radiotherapy. The use of more effective therapy, which grants a greater free disease survival and less later related effects it is very wanted. Thus, the search of new therapeutic targets became very important for childhood treatment. These targets can be related to cellular…
| 1 / 1 | Ongoing grants |
| 1 / 1 | Completed research grants |
| 3 / 3 | Completed scholarships in Brazil |
| 3 / 3 | Completed scholarships abroad |
| 8 / 8 | All research grants and scholarships |
| Associated processes | |